File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy

TitleReal-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy
Authors
KeywordsAsian
liver cancer
treatment
viral hepatitis
viral suppression
Issue Date2020
PublisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
Citation
The Journal of Infectious Diseases, 2020, v. 221 n. 3, p. 389-399 How to Cite?
AbstractBackground: Patients on oral antiviral (OAV) therapy remain at hepatocellular carcinoma (HCC) risk. Risk prediction tools distinguishing treated patients with residual HCC risk are limited. The aim of this study was to develop an accurate, precise, simple-to-use HCC risk score using routine clinical variables among a treated Asian cohort. Methods: Adult Asian chronic hepatitis B (CHB) patients on OAV were recruited from 25 centers in the United States and the Asia-Pacific region. Excluded persons were coinfected with hepatitis C, D, or human immunodeficiency virus, had HCC before or within 1 year of study entry, or their follow-up was <1 year. Patients were randomized to derivation and validation cohorts on a 2:1 ratio. Statistically significant predictors from multivariate modeling formed the Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV (REAL-B) score. Results: A total of 8048 patients were randomized to the derivation (n = 5365) or validation group (n = 2683). The REAL-B model included 7 variables (male gender, age, alcohol use, diabetes, baseline cirrhosis, platelet count, and alpha fetoprotein), and scores were categorized as follows: 0–3 low risk, 4–7 moderate risk, and 8–13 high risk. Area under receiver operating characteristics were >0.80 for HCC risk at 3, 5, and 10 years, and these were significantly higher than other risk models (p < .001). Conclusions: The REAL-B score provides 3 distinct risk categories for HCC development in Asian CHB patients on OAV guiding HCC surveillance strategy.
Persistent Identifierhttp://hdl.handle.net/10722/284490
ISSN
2019 Impact Factor: 5.022
2015 SCImago Journal Rankings: 4.000

 

DC FieldValueLanguage
dc.contributor.authorYang, HI-
dc.contributor.authorYeh, ML-
dc.contributor.authorWong, GL-
dc.contributor.authorPeng, CY-
dc.contributor.authorChen, CH-
dc.contributor.authorTrinh, HN-
dc.contributor.authorCheung, KS-
dc.contributor.authorXie, Q-
dc.contributor.authorSu, TH-
dc.contributor.authorKozuka, R-
dc.contributor.authorLee, DH-
dc.contributor.authorOgawa, E-
dc.contributor.authorZhao, C-
dc.contributor.authorNing, HB-
dc.contributor.authorHuang, R-
dc.contributor.authorLi, J-
dc.contributor.authorZhang, JQ-
dc.contributor.authorIde, T-
dc.contributor.authorXing, H-
dc.contributor.authorIwane, S-
dc.contributor.authorTakahashi, H-
dc.contributor.authorWong, C-
dc.contributor.authorWong, C-
dc.contributor.authorLin, CH-
dc.contributor.authorHoang, J-
dc.contributor.authorLe, A-
dc.contributor.authorHenry, L-
dc.contributor.authorToyoda, H-
dc.contributor.authorUeno, Y-
dc.contributor.authorGane, EJ-
dc.contributor.authorEguchi, Y-
dc.contributor.authorKurosaki, M-
dc.contributor.authorWu, C-
dc.contributor.authorLiu, C-
dc.contributor.authorShang, J-
dc.contributor.authorFurusyo, N-
dc.contributor.authorEnomoto, M-
dc.contributor.authorKao, JH-
dc.contributor.authorYuen, MF-
dc.contributor.authorYu, ML-
dc.contributor.authorNguyen, MH-
dc.date.accessioned2020-08-07T08:58:24Z-
dc.date.available2020-08-07T08:58:24Z-
dc.date.issued2020-
dc.identifier.citationThe Journal of Infectious Diseases, 2020, v. 221 n. 3, p. 389-399-
dc.identifier.issn0022-1899-
dc.identifier.urihttp://hdl.handle.net/10722/284490-
dc.description.abstractBackground: Patients on oral antiviral (OAV) therapy remain at hepatocellular carcinoma (HCC) risk. Risk prediction tools distinguishing treated patients with residual HCC risk are limited. The aim of this study was to develop an accurate, precise, simple-to-use HCC risk score using routine clinical variables among a treated Asian cohort. Methods: Adult Asian chronic hepatitis B (CHB) patients on OAV were recruited from 25 centers in the United States and the Asia-Pacific region. Excluded persons were coinfected with hepatitis C, D, or human immunodeficiency virus, had HCC before or within 1 year of study entry, or their follow-up was <1 year. Patients were randomized to derivation and validation cohorts on a 2:1 ratio. Statistically significant predictors from multivariate modeling formed the Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV (REAL-B) score. Results: A total of 8048 patients were randomized to the derivation (n = 5365) or validation group (n = 2683). The REAL-B model included 7 variables (male gender, age, alcohol use, diabetes, baseline cirrhosis, platelet count, and alpha fetoprotein), and scores were categorized as follows: 0–3 low risk, 4–7 moderate risk, and 8–13 high risk. Area under receiver operating characteristics were >0.80 for HCC risk at 3, 5, and 10 years, and these were significantly higher than other risk models (p < .001). Conclusions: The REAL-B score provides 3 distinct risk categories for HCC development in Asian CHB patients on OAV guiding HCC surveillance strategy.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org-
dc.relation.ispartofThe Journal of Infectious Diseases-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.subjectAsian-
dc.subjectliver cancer-
dc.subjecttreatment-
dc.subjectviral hepatitis-
dc.subjectviral suppression-
dc.titleReal-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy-
dc.typeArticle-
dc.identifier.emailCheung, KS: cks634@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityCheung, KS=rp02532-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/infdis/jiz477-
dc.identifier.pmid31550363-
dc.identifier.scopuseid_2-s2.0-85077946812-
dc.identifier.hkuros312208-
dc.identifier.volume221-
dc.identifier.issue3-
dc.identifier.spage389-
dc.identifier.epage399-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats